Get access
Clinical & Experimental Allergy

Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans

Authors

  • M. KUMLIN,

    Corresponding author
    1. Departments of Medical Biochemistry and Biophysics, Karolinska Inststutet, Stockholm, Sweden
    2. Departments of Physiology and Pharmacology, Karolinska Inststutet, Stockholm, Sweden
      Dr M. Kumlin, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden.
    Search for more papers by this author
  • F. STENSVAD,

    1. Departments of Physiology and Pharmacology, Karolinska Inststutet, Stockholm, Sweden
    Search for more papers by this author
  • L. LARSSON,

    1. Departments of Physiology and Pharmacology, Karolinska Inststutet, Stockholm, Sweden
    Search for more papers by this author
  • B. DAHLÉN,

    1. Departments of Medicine at Karolinska Hospital, Karolinska Inststutet, Stockholm, Sweden
    Search for more papers by this author
  • S.-E. DAHLEN

    1. Departments of Medicine at Karolinska Hospital, Karolinska Inststutet, Stockholm, Sweden
    2. Institute of Environmental Medicine, Karolinska Inststutet, Stockholm, Sweden
    Search for more papers by this author

Dr M. Kumlin, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden.

Summary

To monitor endogenous production of cysteinyl-containing leukotrienes, the end-metabolite leukotriene E4 (LTE4) was analysed in urine. Results obtained with a sensitive enzyme immunoassay (EIA), performed on crude urine samples correlated well with data obtained from a previously reported radioimmunoassay. Enzyme immunoassay analysis of unextracted urine was justified by an excellent agreement between analyses in crude samples and measurements achieved after purification on solid phase extraction followed by separation on reversed-phase high performance liquid chromatography. Moreover, LTE4 was stable in urine samples stored at -20°C, for months without the addition of preservatives. The stability of LTE4 in urine was not improved by addition of the antioxidant 4-hydroxy-TEMPO and pH adjustment to 9. As assessed by EIA analysis in crude urine samples, baseline values for urinary leukotriene E4 were not significantly different between atopic asthmatic subjects and non-asthmatic individuals, and there was no diurnal variation in urinary excretion of LTE4 in healthy subjects. However, we confirmed earlier data on significantly higher basal levels of urinary LTE4 in aspirin-intolerant asthmatics. In addition, a post-challenge increase in urinary LTE4 levels was detected in association with allergeninduced airway obstruction in atopic asthmatics. The per cent increase in urinary LTE4 was similar, irrespective of whether the samples were purified or not prior to EIA. Thus, combined with random validation by high performance liquid chromatography, the strategy of direct EIA of serially diluted urine samples was found to be a good index of in vivo production of leukotrienes. This was further reinforced by the demonstration that pretreatment with the leukotriene biosynthesis inhibitor Bay × 1005 inhibited the post allergen-challenge increase in urinary LTE4, as shown both with unpurilied and purified samples.

Get access to the full text of this article

Ancillary